Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 1.00 |
| ▸ | PPP6C | O00743 | 1/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PPP5C | P53041 | 1/20 | 1.00 |
| ▸ | PPP2CA | P67775 | 1/20 | 1.00 |
| ▸ | PPP2R5A | Q15172 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calyculin A SCHEMBL29406338 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL4295478 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL21408822 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin B SCHEMBL29809573 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL82924 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL4299349 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| SCHEMBL15919331 | 0.95 | PTPN1 (0.91) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL4291014 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL29536011 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL1443597 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1770 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683654-A1 | SIRP VARIANTS AND USES THEREOF | Li, Wangzhi (US) | 2026-01-28 | — | — | EP | claimed |
| US-12440479-B2 | Prevention or treatment of chronic organ injury | GEORG-AUGUST-UNIVERSITAET GOETTINGEN, STIFTUNG OEFFENTLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2025-10-14 | — | — | US | claimed |
| US-20250295693-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2025-09-25 | — | — | US | claimed |
| EP-3966344-B1 | KINASE SCREENING ASSAYS | UNIV NEWCASTLE (GB) | 2025-06-25 | — | — | EP | claimed |
| WO-2024213119-A1 | PH-SENSITIVE CD47-BINDING DOMAINS AND USES THEREOF | ADAPTOCUE, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024193635-A1 | SIRP VARIANTS AND USES THEREOF | LI, Wangzhi (US) | 2024-09-26 | — | — | WO | claimed |
| US-12064426-B2 | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | Genosco Inc. (US) | 2024-08-20 | — | — | US | claimed |
| EP-4387991-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | Julius-Maximilians-Universität Würzburg (DE) | 2024-06-26 | — | — | EP | claimed |
| CN-117305224-A | Method for obtaining definitive endoderm cells from human pluripotent stem cells by differentiation using myosin activator or Piezo1 activator | 武汉大学 | 2023-12-29 | — | — | CN | claimed |
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2002068603-A9 | MATERIALS AND METHODS FOR THE INDUCTION OF PREMATURE CHROMOSOME CONDENSATION | HENRY M JACKSON FOUNDATION (US) | 2003-03-20 | — | — | WO | claimed |
| EP-0696730-B1 | Use of an inhibitor of serine/threonine protein phosphatases to induce premature chromosome condensation (PCC) | GOTOH EISUKE (JP) | 2002-11-06 | — | — | EP | claimed |
| US-20020132326-A1 | Process for activating a kinase | HEMMINGS BRIAN A (CH) | 2002-09-19 | — | — | US | claimed |
| WO-2002068603-A2 | MATERIALS AND METHODS FOR THE INDUCTION OF PREMATURE CHROMOSOME CONDENSATION | THE HENRY M. JACKSON FOUNDATION (US) | 2002-09-06 | — | — | WO | claimed |
| US-6369294-B1 | ISOLATION OF PRIMORDIAL GERM CELLS, CULTURING THESE CELLS TO PRODUCE PRIMORDIAL GERM CELL-DERIVED CELL LINES, METHODS FOR TRANSFORMING BOTH THE PRIMORDIAL GERM CELLS AND THE CULTURED CELL LINES | TEXAS A&M UNIVERSITY SYSTEM | 2002-04-09 | — | — | US | claimed |
| WO-2001057530-A1 | METHOD AND APPARATUS FOR SIGNAL TRANSDUCTION PATHWAY PROFILING | IMMUNOMATRIX INC. (US) | 2001-08-09 | — | — | WO | claimed |
| US-6110679-A | GENERATING COMPRESSED NUCLEUS MATERIAL BY INCUBATION OF CELLS WITH ENZYME INHIBITORS | GOTOH EISUKE (JP) | 2000-08-29 | — | — | US | claimed |
| WO-1999041281-A1 | MODULATION OF HEDGEHOG-MEDIATED SIGNALING PATHWAY | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1999-08-19 | — | — | WO | claimed |
| EP-0696730-A1 | Agents and a method of chromosome preparation using protein phosphatase inhibitors induced premature chromosome condensation (PCC) technique | Gotoh, Eisuke (JP) | 1996-02-14 | — | — | EP | claimed |
| EP-0551200-A1 | Protein phosphatase inhibitors for use in therapy | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1993-07-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064426-B2 | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | ROCK2, ROCK1, MYLK3 | PTPN1 791/4885PPP6C 244/4885PPP1CC 291/4885 |
| US-12440479-B2 | Prevention or treatment of chronic organ injury | FKBP2, DUSP3, FKBP1A | PTPN1 202/4885PPP6C 31/4885PPP1CC 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.